Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

Autor: Zavras,PD, Wang,Y, Gandhi,A, Lontos,K, Delgoffe,GM

Publikováno v: OncoTargets and Therapy.

PD Zavras,1 Y Wang,2,3 A Gandhi,4 K Lontos,2,5 GM Delgoffe2,61Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dovemedicalp::424716dbba71200dfea0ac4810b8e5c5
https://www.dovepress.com/evaluating-tisagenlecleucel-and-its-potential-in-the-treatment-of-rela-peer-reviewed-article-OTT

Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism.

Autor: Peralta RM; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Xie B; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lontos K; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA., Nieves-Rosado H; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Spahr K; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Joshi S; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ford BR; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA., Quann K; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA., Frisch AT; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Dean V; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Philbin M; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Cillo AR; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Center for Systems Immunology, University of Pittsburgh, Pittsburgh, PA, USA., Gingras S; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA., Poholek AC; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA., Kane LP; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Rivadeneira DB; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Delgoffe GM; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. gdelgoffe@pitt.edu.; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. gdelgoffe@pitt.edu.

Publikováno v: Nature immunology [Nat Immunol] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.

LAG-3 and PD-1 synergize on CD8 ⁺ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity.

Autor: Andrews LP; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Butler SC; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Cui J; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Cillo AR; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Cardello C; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Liu C; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Brunazzi EA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Baessler A; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Xie B; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Kunning SR; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ngiow SF; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Huang YJ; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Manne S; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Sharpe AH; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Delgoffe GM; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Wherry EJ; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kirkwood JM; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Bruno TC; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Workman CJ; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Vignali DAA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: dvignali@pitt.edu.

Publikováno v: Cell [Cell] 2024 Aug 08; Vol. 187 (16), pp. 4355-4372.e22.

An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance.

Autor: Shao L; Cancer Virology Program, Pittsburgh, Pennsylvania.; Department of Microbiology and Molecular Genetics, Pittsburgh, Pennsylvania., Srivastava R; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Delgoffe GM; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Thorne SH; Cancer Virology Program, Pittsburgh, Pennsylvania.; KaliVir Immunotherapeutics, Inc., Pittsburgh, Pennsylvania., Sarkar SN; Cancer Virology Program, Pittsburgh, Pennsylvania.; Department of Microbiology and Molecular Genetics, Pittsburgh, Pennsylvania.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2024 Jun 04; Vol. 12 (6), pp. 779-790.

Integrating innate and adaptive immunity in oncolytic virus therapy.

Autor: DePeaux K; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Delgoffe GM; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: gdelgoffe@pitt.edu.

Publikováno v: Trends in cancer [Trends Cancer] 2024 Feb; Vol. 10 (2), pp. 135-146. Date of Electronic Publication: 2023 Oct 23.